Kyle Fang（方凯）

Kyle Fang is a pharmaceutical professional with over 10 years of experience in both local companies and multinational corporations. They co-founded Helix & Bond Pharmaceuticals, where they managed projects and developed business strategies until its merger with Accela ChemBio. Following this, Kyle held roles including External Collaboration Manager at AstraZeneca and VP at Accela ChemBio and SyncoZymes, focusing on marketing, sales, and business development. Currently, Kyle serves as the GM of CRI at Pharmaron, leveraging extensive expertise in pharmaceutical R&D outsourcing and strategic management. Kyle earned a Ph.D. in Organic Chemistry from the Shanghai Institute of Organic Chemistry and completed a postdoctoral fellowship in Medicinal Chemistry at the University of Michigan.